Abboud H - Search Results

1

A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.

Abboud H, Coyne D, Smolenski O, Anger M, Lunde N, Qiu P, Hippensteel R, Pradhan RS, Palaparthy RV, Kavanaugh A, Melnick JZ, Williams LA, Batlle D. Abboud H, et al. Am J Nephrol. 2006;26(1):105-14. doi: 10.1159/000092033. Epub 2006 Mar 14. Am J Nephrol. 2006. PMID: 16543714 Clinical Trial.

2

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Coyne D, et al. Among authors: abboud h. Am J Kidney Dis. 2006 Feb;47(2):263-76. doi: 10.1053/j.ajkd.2005.10.007. Am J Kidney Dis. 2006. PMID: 16431255 Clinical Trial.

3

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM. Ross EA, et al. Among authors: abboud h. Am J Nephrol. 2008;28(1):97-106. doi: 10.1159/000109398. Epub 2007 Oct 3. Am J Nephrol. 2008. PMID: 17914251 Clinical Trial.

4

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Sprague SM, et al. Among authors: abboud h. Clin J Am Soc Nephrol. 2009 Jan;4(1):178-85. doi: 10.2215/CJN.02830608. Epub 2008 Dec 3. Clin J Am Soc Nephrol. 2009. PMID: 19056618 Free PMC article. Clinical Trial.

5

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. Martin KJ, et al. Among authors: abboud h. J Am Soc Nephrol. 1998 Aug;9(8):1427-32. doi: 10.1681/ASN.V981427. J Am Soc Nephrol. 1998. PMID: 9697664 Clinical Trial.

6

Genome scan for determinants of serum uric acid variability.

Nath SD, Voruganti VS, Arar NH, Thameem F, Lopez-Alvarenga JC, Bauer R, Blangero J, MacCluer JW, Comuzzie AG, Abboud HE. Nath SD, et al. Among authors: abboud he. J Am Soc Nephrol. 2007 Dec;18(12):3156-63. doi: 10.1681/ASN.2007040426. Epub 2007 Oct 31. J Am Soc Nephrol. 2007. PMID: 17978310

7

Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.

Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Martin KJ, et al. Among authors: abboud h. Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S61-6. doi: 10.1053/ajkd.1998.v32.pm9808145. Am J Kidney Dis. 1998. PMID: 9808145 Clinical Trial.

8

Diabetic nephropathy among Mexican Americans.

Debnath S, Thameem F, Alves T, Nolen J, Al-Shahrouri H, Bansal S, Abboud HE, Fanti P. Debnath S, et al. Among authors: abboud he. Clin Nephrol. 2012 Apr;77(4):332-44. doi: 10.5414/cn107487. Clin Nephrol. 2012. PMID: 22445478 Free PMC article. Review.

9

Mitogenic signaling via platelet-derived growth factor beta in metanephric mesenchymal cells.

Wagner B, Ricono JM, Gorin Y, Block K, Arar M, Riley D, Choudhury GG, Abboud HE. Wagner B, et al. J Am Soc Nephrol. 2007 Nov;18(11):2903-11. doi: 10.1681/ASN.2006111229. Epub 2007 Oct 17. J Am Soc Nephrol. 2007. PMID: 17942966

10

NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis.

Al-Shahrouri HZ, Ramirez P, Fanti P, Abboud H, Lorenzo C, Haffner S. Al-Shahrouri HZ, et al. Among authors: abboud h. Clin Nephrol. 2010 Mar;73(3):180-9. doi: 10.5414/cnp73180. Clin Nephrol. 2010. PMID: 20178716

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

375 results

Search Page

Filters